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The role of urokinase plasminogen activator and
plasmin activator inhibitor-1 on vein wall
remodeling in experimental deep vein thrombosis
Joe F. Baldwin, BS, Vikram Sood, BS, Megan A. Elfline, MS, Cathy E. Luke, LVT,
Nicholas A. Dewyer, MD, Jose A. Diaz, MD, Dan D. Myers, DVM, Thomas Wakefield, MD, and
Peter K. Henke, MD, Ann Arbor, Mich
Objective: Deep vein thrombosis (DVT) resolution instigates an inflammatory response, resulting in vessel wall damage
and scarring. Urokinase-plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), are
integral components of the fibrinolytic system, essential for venous thrombosis (VT) resolution. This study determined
the vein wall response when exposed to increased and decreased plasmin activity.
Methods: A mouse inferior vena cava (IVC) ligation model in uPA / or PAI-1 / and their genetic wild types
(B6/SvEv and C57/BL6, respectively) was used to create stasis thrombi, with tissue harvest at either 8 or 21 days. Tissue
analysis included gene expression of vascular smooth muscle cells (alpha smooth muscle actin [SMA], SM22) and
endothelial marker (CD31), by real-time polymerase chain reaction, enzyme-linked immunosorbent assay, matrix
metalloproteinase (MMP)-2 and -9 activity by zymography, and vein wall collagen by picro-Sirius red histologic analysis.
A P < .05 was considered significant.
Results: Thrombi were significantly larger in both 8-day and 21-day uPA / as compared with wild type (WT) and
were significantly smaller in both 8-day and 21-day PAI-1 / as compared with WT. Correspondingly, 8-day plasmin
levels were reduced in half in uPA / and increased three-fold in PAI-1 / when compared with respective WT
thrombi (P < .05; n  5-6). The endothelial marker CD31 was elevated two-fold in PAI-1 / mice at 8 days, but
reduced 2.5-fold at 21 days in uPA / as compared with WT (P  .02; n  5-6), suggesting less endothelial
preservation. Vein wall vascular smooth muscle cell (VSMC) gene expression showed that 8-day and 21-day PAI-1/
mice had 2.3- and 3.8-fold more SM22 and 1.8- and 2.3-fold more SMA expression than respective WT (P < .05; n 
5-7), as well as 1.8-fold increased SMA () cells (P < .05; n  3-5). No significant difference in MMP-2 or -9 activity
was found in the PAI-1 / mice compared with WT, while 5.4-fold more MMP-9 was present in 21-day WT than
21-day uPA/ (P .03; n 5). Lastly, collagen wastwo-fold greater at 8 days in PAI-1/ IVC as compared with
WT (P  .03; n  6) with no differences observed in uPA / mice.
Conclusions: In stasis DVT, plasmin activity is critical for thrombus resolution. Divergent vein wall responses occur with
gain or loss of plasmin activity, and despite smaller VT, greater vein wall fibrosis was associated with lack of PAI-1.
(J Vasc Surg 2012;56:1089-97.)
Clinical Relevance:DVT resolution is dependent on many factors. Clinical studies suggest that slowly resolving extensive
DVTs are associated with greater likelihood of post-thrombotic syndrome, and this is experimentally modeled by vein
wall fibrosis and inflammation. The current study suggests a more complex relationship in that the plasmin-mediated
events are central to thrombus resolution as well as to how the vessel wall responds. Surprisingly, a larger thrombus from
a stasis model is not associated with greater vein wall damage. Thus, novel modalities such as PAI-1 inhibition may
require supplemental anticoagulants for full efficacy.
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mDeep vein thrombosis (DVT) is estimated to affect
more than 300,000 people in North America and 460,000
people in the European Union each year.1 Approximately
one-third of patients with DVT will develop post-thrombotic
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http://dx.doi.org/10.1016/j.jvs.2012.02.054yndrome (PTS),2,3 which impairs quality of life and pro-
uctivity.4 The rate at which DVT resolves has been found
o correlate with the development of PTS.5 Little is known
bout what occurs at the vein wall level after DVT in
elation to PTS. Current management is limited to elastic
ompression stockings, and other approaches such as pneu-
atic compression units and short-term use of venoactive
gents are being explored.6,7
DVT resolution is an inflammatory process that affects
essel wall remodeling.8 Leukocytes, chemokines, and he-
ostatic regulators play a role in both thrombosis and vein
all inflammation.9-11 Vein wall remodeling in the rodent
fter venous thrombosis (VT) involves profibrotic growth
actors, collagen deposition, a change in the vein wall cell
ilieu, and matrix metalloproteinase (MMP) expression
nd activation.8 Currently, both the mechanism of throm-
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October 20121090 Baldwin et albus formation and the length of contact time between the
thrombus and the vein wall are thought to influence the
vessel wall response.12 After vascular injury, there is denu-
dation of the endothelial lining, deposition of new extra-
cellular matrix, increased vascular smooth muscle cell
(VSMC) proliferation and migration, and a switch of
VSMC to a cellular synthetic state.13,14 While all of these
changes have been characterized in the arterial vasculature,
the vessel wall undergoing DVT in the presence of in-
creased or decreased plasmin has not been similarly charac-
terized.
Plasmin, a serine protease formed by the cleavage of its
proenzyme plasminogen, is the primary fibrinolytic enzyme
responsible for DVT resolution. Plasminogen activators are
serine proteases that activate plasminogen to the enzyme
plasmin. The major plasminogen activator found in circu-
lation is urokinase-plasminogen activator (uPA), and the
major inhibitor of plasminogen activators is plasminogen
activator inhibitor-1 (PAI-1). While the studies on the role
of PAI-1 and risk of DVT have been inconsistent,15,16
impaired thrombus resolution has been observed in
uPA / mice.17 Moreover, the role of PAI-1 in vascular
response depends on the model, genetic background, and
timing of analysis.18 By manipulating uPA and PAI-1
through genetically deleted mice, corresponding larger and
smaller VTs can also be indirectly examined to assess the
vein wall effect.
In this study, we hypothesize that greater plasmin
activity (PAI-1 /) would be associated with less vein
wall fibrosis, and less plasmin activity (uPA/) would be
associated with greater fibrosis in a stasis model.
METHODS
Animal model. Male mice from B6/SvEv wild type
(WT), B6/SvEv uPA / (kindly donated by Drs D.
Collen and P. Carmiliet), C57BL6 WT and C57BL6
PAI-1 / (kindly donated by Dr D. Lawrence) were
used for all studies. Because of genetic background differ-
ences, each genetic deletion group was only compared with
their respective genetic background controls. All animal
studies were done with University of Michigan Animal Use
Committee approval. For all surgical procedures, the mice
underwent general anesthesia with isoflorane/O2. Stasis
venous thrombosis was induced by inferior vena cava (IVC)
ligation.9,12,13 A laparotomy with ligation of the IVC be-
low the renal veins and division of all visible side branches
was done. At sacrifice, at 8 and 21 days postligation, the
thrombosed IVC was carefully dissected and removed for
histologic and biochemical studies. The thrombus is easy to
remove at or before 8 days. After this, the thrombus and
vein wall form a residual fibrosed remnant through 21 days.
Thus, at 8 days, the thrombus and vein wall were able to be
assessed separately, while at 21 days, these were examined
together. This time frame was chosen to correlate with mid
to late vein wall remodeling after DVT, and when PTS
develops.
Histology/immunohistochemical/collagen staining.
Tissue samples were formalin fixed, paraffin embedded, and Put into 5-m sections as described.9,13 Nonspecific sites
ere blocked with normal serum, and sections were incu-
ated with primary antibodies to Mac2 (1:200; Cedarlane
aboratories, Burlington, NC), alpha smooth muscle actin
SMA; 1:500; Santa Cruz Biotechnology, Santa Cruz,
alif), and fibroblast specific protein-1 (FSP-1; 1:500;
anta Cruz Biotechnology). A species-specific avidin-biotin
omplex (ABC) peroxidase kit for either rabbit or rat
Vector Laboratories Inc, Burlingame, Calif) was used ac-
ording to the manufacturer’s instructions for the corre-
ponding secondary antibody and subsequent steps. Color
evelopment was performed with diaminobenzidine
DAB). The slides were counterstained with hematoxylin.
n a blinded fashion, positive cells in five high-power fields
1000x) radially around the IVCwere counted and totaled.
Picrosirius red staining to quantify collagen content
as performed as described.19,20 These sections were then
nalyzed in crossed-plane polarized light from amonochro-
atic source to assess crosslinked collagen. Two images for
ach were obtained using a Zeiss Axio M1 scope and Zeiss
xioVision software (Carl Zeiss Microimaging GmbH,
öttingen, Germany) at 0 and 90 degrees to the plane of
olarization, in order to capture the birefringence of fibers
xtinguished in one direction. The images were analyzed
lindly utilizing National Institutes of Health ImageJ soft-
are. The area corresponding to the vein wall was selected
s a region of interest, and then the image underwent
hreshold segmentation to differentiate collagen from
ther (mainly cellular and empty space) components of the
ein wall. A vein wall collagen score was assigned by the
ormula [(% birefringent area)  (measured vein wall
rea)]/(total specimen area).
To account for noncollagen vein wall changes, intimal
hickness scoring was assessed from hematoxylin and eosin
ections as described.21 A consistent midsection throm-
osed IVC segment was used for all histologic analysis.22-24
Real-time quantitative polymerase chain reaction.
xpression of -actin, SMA, SM22, CD31, procollagen I
Col1a2), and procollagen III (Col3a) was determined as
ollows: RNA was isolated by treatment of IVC wall seg-
ents with TRIzol reagent and reverse transcribed by
ncubating with Oligo(dT) primer and M-MLV Reverse
ranscriptase (Life Technologies, Carlsbad, Calif) at 94°C
or 3 minutes followed by 40°C for 70 minutes. The
esultant cDNA was amplified by Taq Polymerase (Pro-
ega, Madison, Wisc) in the Rotogene quantitative poly-
erase chain reaction system (Qiagen Inc, Valencia, Calif).
YBR Intercalating Dye (Roche, Indianapolis, Ind) was
sed to monitor levels of cDNA amplification for each
ene. Primer sequences were derived using validated
rimer sequences from Superarray (Fredrick, Md). Roto-
ene quantification utilizes the cycle threshold (Ct) for the
ene of interest normalized to the housekeeping gene
-actin. Relative mRNA expression is calculated by the
ormula 2-(Ct target gene-Ct reference gene), and cycle lengths
sed are within the exponential phase of the polymerase
hain reaction.14 These primers include -actin
PM02945A Ref Pos 164 to 183; SMA PPMM04483A
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Volume 56, Number 4 Baldwin et al 1091Ref Pos 1107; SM22 PPM03802C Ref Pos 639 to 657;
CD31 PPM03802C Ref Pos 1844; Col1a2 PPM04448E
Ref Pos 4816; and Col3a PPM04784B Ref Pos 4380.
Enzyme-linked immunosorbent assay. Tissue ho-
mogenate of the thrombus for plasmin and fibrinogen (Inno-
vative Research, Novi, Mich), collagen IV (Exocell, Philadel-
phia, Pa), and thrombin-antithrombin complex (TAT;
EnzymeResearchLaboratories, SouthBend, Ind)were deter-
mined using a commercial kit according to manufacturer’s
instructions. Quantification of peptidemediators was normal-
ized to total protein in the sample as described.9,13
Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis gelatin zymography. As described,9,10 homog-
enized IVC tissue and thrombus were subjected to sub-
strate zymography for MMP-2 and -9 using precast 10%
sodium dodecyl sulfate polyacrylamide gels containing 1
mg/mL of gelatin (unless otherwise stated, all zymography
supplies were fromNovex, SanDiego, Calif). Densitometry
analysis was performed using a FOTO/Analyst CCD cam-
era (Fotodyne, Hartland, Wisc) and GEL-Pro Analyzer
software version 3.1 (Media Cybernetics, Silver Springs,
Md). Pro and active MMP-2 and -9 activity optical densi-
Fig 1. A, Thrombus size was larger in urokinase-plasm
(WT). B, Plasmin activity was decreased in uPA / at
fibrinogen content was lower, as was thrombin-antithro
with WT.D, At 8 and 21 days, venous thromboses (VT)
/ mice as compared with WT. E, Thrombus size was
activity was increased in PAI-1/ at 8 days as comparties were summed and normalized to total protein. (Statistical analysis. All data are represented asmean SE.
wo-tailed unpaired Student’s t-test was used for compar-
son between control and genetically deleted group
GraphPAD Prism, San Diego, Calif); P .05 was assigned
ignificance.
ESULTS
Thrombus resolution is altered in uPA / and
AI-1 / mice. As measured by weight to length of the
hrombosed IVC, uPA / mice had significantly larger
hrombi thanWT at both 8 days (n 13; P .03) and at 21
ays (n 17; P	 .01; Fig 1, A). This phenotype is consistent
ith past studies derived from a slightly different model.17
orrespondingly, uPA / mice had less plasmin activity,
ess thrombus fibrinogen, andTAT at 8 days thanWT (n 6;
 .02; Fig 1, B-D). Conversely, PAI-1 / mice had
ignificantly smaller thrombi thanWT at both 8 days (n 12;
	 .01) and at 21days (n17;P	 .01; Fig 1, E). ThePAI-1
/ mice had significantly more plasmin activity at 8 days
n  6; P  .03; Fig 1, F), but no differences in thrombus
brinogen or TAT (data not shown).However, no significant
ifference in plasmin in either group was found at 21 days
en activator (uPA) / as compared with wild type
s as compared with WT; C, Despite larger thrombi, the
complex (TAT) at 8 days in uPA / mice compared
smaller in the plasminogen activator inhibitor-1 (PAI-1)
ler in the PAI-1/as compared with WT. F, Plasmin
th WT. *P 	 .05.inog
8 day
mbin
were
smaldata not shown). Grossly, the thrombus histomorphology
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October 20121092 Baldwin et alwas different with a large nonnucleated cell thrombus in uPA
/mice and a small cellular thrombus in PAI-1/ at 21
days (Fig 2, A-D). While the early 2-day time point was not a
focus of this study, we found the thrombi were larger in uPA
/ as compared with WT (4.0  0.17 vs 3.1  0.2
mg/mm; n 4-6; P .009). Conversely, PAI-1/ were
not significantly different at the 2-day time point (3.0 .24 vs
2.6 0.10 mg/mm; n 7-8, P .24).
Vein wall endothelial gene expression in uPA /
and PAI-1/mice. Denudation of the endothelium is
associated with the mechanical stretch and inflammatory
injury caused by thrombi.10,22,25 There was no difference
in 8-day CD31 gene expression, an endothelial marker, in
uPA / as compared with WT (0.20  .14 vs .08  .4;
n  6; P  .48) However, there was 2.5-fold greater
CD31 gene expression in 21-day WT than in 21-day
uPA/mice (n 5-6; P .02) (Fig 3, A). Conversely,
PAI-1/micehad two-foldgreaterCD31gene expression at
8 days compared withWT (n 5-7; P .03; Fig 3, B).
As a measure of the noncollagen component of the vein
wall, the intimal thickness score was used.26 A loss of
intimal thickness was found at 8 days in uPA / mice
compared with WT (Fig 3, C-E). No significant difference
Fig 2. Hematoxylin and eosin stained inferior vena
urokinase-plasminogen activator (uPA) / (B) examp
thrombus. The 21-day WT (C) and plasminogen activ
thrombus morphology and cellularity. T, Thrombus.was observed in the uPA / intimal thickness as com- tared with WT at 21 days. No difference in intimal thick-
ess was found in the PAI-1/ as compared with WT at
or 21 days (data not shown).
Vein wall fibrosis is increased in PAI-1 / after
T. Vein walls become thickened and fibrotic in stasis
T in both mice and in humans.10,12,27 We found that
rocollagen I and III gene expression was elevated three-
old in PAI-1 / as compared with WT (P 	 .05; Fig
, A and B). No differences in these gene expressions in
rocollagen I or III gene expression in uPA / as
ompared with WT were found (not shown). Consis-
ently, vein wall collagen content was elevated two-fold
n 8-day PAI-1/ as compared with WT (2.2 .45 vs
.9  .16 AU; n  6; P  .03), and a trend at 21days
6.2 1.8 vs 3.1 1 AU, n 5-6; P .13; Fig 4, C-E).
o significant differences in vein wall collagen content
ere found at 8 or 21 days in uPA / as compared
ith WT.
Vein wall cellular and proteinase response in
PA / and PAI-1 / mice after VT. To assess if
here were differences in matrix VSMC, we assessed for
ene expression and for antigen expression by immunohis-
(IVC) sections of 21-day wild type (WT) (A) and
ote the large and relative acellularity of the uPA /
inhibitor-1 (PAI-1) / (D) are shown with similarcava
les. N
atorochemistry. PAI-1 / mice had significantly more vein
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.03) and 21 days (n 5-7; P .03; Fig 5, A), than WT. In
addition, PAI-1 / mice also had significantly more
SMA expression at both 8 days (n 5-7; P .01) and 21
days (n 5-7; P .03; Fig 5, B). We found a correspond-
ing 1.8-fold increase in SMA (
) cells at 8 days in PAI-1
/ as compared withWT (n 3-5; P .02; Fig 5, C-E).
No difference in fibroblast type cells were found (FSP-1 

cells: 3.7  0.3 vs 3.4  7; n  3-5; P  .8) at 8 days in
PAI-1 / compared with WT. No significant difference
was found in uPA / vein wall VSMC marker gene
expression as compared with WT at 8 or 21 days.
Monocytes direct vascular response to injury, including
the vein wall response. At 8 days, no significant difference in
monocyte (Mac-2
) vein wall counts was observed in any
of the groups. However, at 21 days, increased monocytes
were found in both the PAI 1 / (19  5 vs 5  1;
n  5; P  .02) and uPA / (33  8 vs 5  2; n  5;
P  .01) vein wall as compared with WT controls.
MMPs are present in the vein wall after VT and metab-
olize the extracellular matrix to allow for VSMCmigration,
Fig 3. Gene expression of the endothelial marker CD
(uPA) / compared with wild type (WT) (A). Con
plasminogen activator inhibitor-1 (PAI-1)/ (B) as c
8-day uPA/ vein wall as compared withWT (C). Mil
but little in the uPA/ vein wall (E). Note again the m
in uPA / thrombi. T, Thrombus; W, wall.proliferation, and vessel remodeling.12,28 Despite an in- sreased plasmin activity level in PAI-1 / mice, no
ignificant difference in vein wall MMP-2 or -9 zymo-
raphic activity was found in PAI-1 / at 8 or 21 days,
hen compared withWT. A significant decrease inMMP-9
ctivity at 21 days in uPA/mice as compared with WT
as found (40 15 vs 10 5 AU/mg protein; n 5; P
03), but no significant differences in MMP-2 activity at 8
r 21 days were found in uPA / or PAI-1 / mice
data not shown).
ISCUSSION
PTS affects up to 30% of people after DVT,2,3 leading
o a significant decrease in quality of life.4 Management of
TS pharmacologically has been limited in part by a lack of
nderstanding the underlying pathophysiology of the dis-
ase. However, observations suggest that rapid DVT reso-
ution is associated with lower risk of PTS,5 but no specific
harmacologic agents are available that directly address this
roblem.6 The main findings of this study suggest that
ncreased or decreased plasmin results in a divergent injury
esponse at the cellular and genetic level. While this study
as reduced in 21-day urokinase-plasminogen activator
ly, CD31 gene expression was increased at 8 days in
red with WT. Vein wall intimal thickness was reduced in
intimal thickening is present in 8-dayWT vein walls (D),
d cellularity of 8-day WT thrombi, but few were present31 w
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of thrombus size may also have contributed to the pheno-
types herein. Presumably, a larger thrombus should confer
greater vein wall damage, both mechanically and due to
presence of inflammatory cells and mediators at the
thrombus-vein wall interface, but this was not the case.
Zhou and colleagues showed early endothelial injury
cracking and denudation after stasis VT, with exposure of
prothrombotic elements.29 We also have shown early en-
dothelial loss with recovery at 2 weeks in a rat model of
stasis VT, with low-molecular-weight heparin associated
with less endothelial loss at 14 days after thrombosis.22 In
the current study, loss of plasmin activity (uPA /) was
not associated with an increase in fibrotic injury, but pri-
marily affected the endothelial response, with less late
CD31 gene expression. Of note, nonthrombosed sham
CD31 gene expression is 20-fold higher than throm-
bosed 8-day IVC expression. This is also counter to our
initial hypothesis that less plasmin would be associated with
worsened fibrotic injury. Our data contrast with the models
of arterial injury where endothelial denudation is associated
Fig 4. Vein wall procollagen I (A) and III (B) gene expr
(PAI-1) / as compared with wild type (WT). By Pico
PAI-1 / compared with WT, and a trend at 21 d
urokinase-plasminogen activator (uPA)/ at 8 or 21
in WT (D), but a greater amount in PAI-1 / vein wwith increased neointimal fibrosis.30,31 Indeed, not only pas no increase in fibrosis observed with loss of uPA, but
he neointimal response was significantly less than control
T. Several factors may account for this difference, includ-
ng the local shear stress, distension, and cellular elements
nique in the venous thrombus. Less thrombin (as mea-
ured by TAT complex) was also observed in the uPA/
hrombi, and thrombin has profibrotic effects.32 Further,
ess fibrinogen, per weight of thrombus, was also found in
he uPA / thrombi, and fibrinogen may stimulate
eukocyte proinflammatory and secondary profibrotic activ-
ties.33 Moreover, lack of uPA in an arterial model was
ssociated with increased vascular injury, but was predom-
nately luminal occlusion and not the vessel wall. Similar to
ur findings, no increase in medial fibrosis was observed in
PA / arterial walls after balloon injury.34
These observations also suggest that the thrombosis
echanism is likely more important than the size of the
hrombus itself in the vein wall injury response. For exam-
le, in the rat model, the greatest injury was observed with
stasis compared with a nonstasis model.10 Supporting this
lso is that despite larger VTs in the rat due to direct
was elevated in 8-day plasminogen activator inhibitor-1
s red analysis, collagen content was elevated at 8 days in
hile no difference in collagen content was found in
C). Birefringence images show a thin vein wall collagen
). P 	 .05. T, Thrombus.ession
siriu
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days (lasmin inhibition, we found less biomechanical evidence
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Volume 56, Number 4 Baldwin et al 1095of vein wall injury.11 Our data in the late vein wall response
(8 days) contrast with the early independence of uPA on
VT resolution. Specifically, early VT resolution in the
uPA / mouse is independent of uPA, and dependent
on MMP-2.24 These observations as well as those of oth-
ers17 highlight the time-dependent and phasic nature of VT
resolution and subsequent vein wall response.
Although the VT were smaller in PAI-1/mice, the
vein wall fibrotic injury at 8 days was greater than in WT
controls. However, these observations are consistent with
the vessel response from experimental arterial injury mod-
els. For example, in both flow restriction and FeCI3 arterial
injury models, as well as myocardial injury, PAI-1 deletion
or exogenous PAI-1 inhibition were associated with in-
creased neointimal hyperplasia.35-37 While we found no
difference in intimal thickness in WT or PAI-1 / mice
after VT, a thickened and collagen-rich vein wall was found
with deletion of PAI-1 /. This phenotype was associ-
ated with increased VSMC gene expression and cell number,
Fig 5. Vascular smooth muscle cell (VSMC) gene marke
(SMA) (B) expression in plasminogen activator inhibito
and 21 days. Medial SMA 
 cells were increased in PA
tology showed the mononuclear medial location of thes
cava (IVC) sections. *P 	 .05; arrows denote (
) cells.suggesting either proliferation or influx of VSMC. Our data co not allow us to determine whichmechanism occurred, but
thers have shown in an arterial injury model that increased
SMCproliferation occurswith lack of PAI-1 andmay be due
o PAI-1’s thrombin inhibitory activity.36 We speculate that
ince TAT levels were not increased in PAI-1/ thrombi,
he role of vitronectin37 or othermigratory processes aremore
mportant than the proliferative effect in our stasis model.
pecifically, PAI-1 may be protective from fibrotic injury by
oth its vitronectin binding role (decreased VSMC prolifera-
ion and migration) and by its antiproteolytic activity.37
oreover, this is in part driven by bone marrow-derived
rogenitor cells that express PAI-1, as PAI-1 competent cells
escued the neointimal hyperplastic injury phenotype.38
astly, others have shown transforming growth factor-beta
ay be elevated in PAI-1 / mice after vascular injury, as
his cytokine has well-documented profibrotic effects.39
The differential role of the monocyte in vein wall
esponse and thrombus resolution after stasis VT has been
ecently reviewed.8,40 Counterintuitively, a greater mono-
wed increased SM22 (A) and alpha smooth muscle actin
PAI-1)/ vein wall compared to wild type (WT) at 8
/ at 8 days as compared with WT (C). Immunohis-
itive cells in WT (D) and PAI-1 / (E) inferior vena
rombus; W, wall.r sho
r-1 (
I-1 
e posyte number is not necessarily associated with greater vein
R1
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P-selectin inhibition was associated with increased vein wall
monocyte influx, but less fibrosis and stiffness.21 Monocyte
subtypes may confer a pro- or anti-inflammatory state de-
pending on the local environment.41 As this was a late
response after stasis thrombus injury, and little significant
difference of phenotypic injury response was observed in
either genotype at 21 days, the mechanistic relevance is not
clear. However, neither PAI-1 / nor uPA / af-
fected monocyte influx at 8 days when the phenotypic
differences were greatest.
Despite an increase in plasmin in the PAI-1 / vein
wall, we did not observe an increase in either MMP-2 or
MMP-9 by zymographic analysis. While plasmin can acti-
vate these MMPs, other mechanisms such as MMP-14 or
MMP-3 also play a major role after vascular injury.42 Our
findings suggest that the thrombus size itself does not affect
MMP activity outside of the elevation associated with the
stasis thrombus model itself.12 Consistent with the known
action of plasmin, less MMP-9 activity was present late in
uPA / mice, but this was not associated with a pheno-
typic difference in vein wall fibrosis. Interestingly, direct
plasmin inhibition in a rat stasis model was associated with
increased MMP-9 and associated with increased biome-
chanical injury.11 Although less plasmin was present in the
uPA / mice and no difference in late vein wall injury
was found, some activity remained and may account for the
difference in vein wall response between the rat and the
mouse. Lastly, after day 8, our model does not allow for
thrombus separation from the vein wall as they are densely
adherent. The decrease in MMP-9 activity may also be due
to fewer thrombus mononuclear cells,17 which are a prime
source of MMP-9.
In humans, the longer the thrombus is in contact with
the vein wall, the greater the damage.5 While this in vivo
study shows promise for PAI-1 as a pharmacologic target
for VT resolution, whether or not exogenous PAI-1 inhi-
bition increases vein wall fibrosis awaits further study, once
exogenous agents become more readily available. More-
over, our model did not allow us to assess if an increased
fibrotic response affects the thrombus adherence and could
lead to decreased embolization to the pulmonary circula-
tion. Nonetheless, a potential translational therapeutic
combination might be a PAI-1 inhibitor in conjunction
with a thrombin specific inhibitor, such as hirudin, that
abolishes the profibrotic effect of PAI-1 inhibitors.36
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